Health Care / Medicine

New Bill Led By Democrats Aims To Cap Medicare Out-Of-Pocket Costs

The Medicare Cost Cap Act seeks to create a $5,000 cap on out-of-pocket costs for traditional Medicare beneficiaries.

The Things To Think About Before Taking Your Biotech Company Public

The biotech IPOs window is now open, but that doesn’t mean every company can go through it.

Is It Likely That The WISeR Model Will Be Repealed?

Congressional Democrats are seeking to repeal the controversial WISeR model, but experts are unsure if their efforts will succeed.

KFF: Insurer Participation In ACA Marketplaces Is Down

KFF’s analysis found that the average number of issuers offering plans on the Marketplaces declined to 9 issuers per state in 2026, compared to 9.6 issuers per state in 2025.

FDA Reversal On uniQure Gene Therapy Is Another Sign Of Renewed Regulatory Flexibility

This gene therapy is the latest in a growing list of rare disease treatments to receive reconsideration from an FDA that appears to be swinging back to regulatory flexibility.

Amgen Turns To An Independent Review To Defend Rare Disease Drug In FDA Crosshairs

FDA concerns about Amgen’s Tavneos were sparked by securities fraud litigation against ChemoCentryx, the company that originally developed the rare disease drug. The FDA wants to withdraw Tavneos’s approval, citing safety risks and alleged manipulation of the drug’s clinical trial data.

What The ‘One Nation, Overcharged’ Campaign Aims To Achieve

One Nation, Overcharged, a campaign backed by the Robert Wood Johnson Foundation, launched to raise awareness of rising healthcare costs.

Former FDA Officials: There’s Opportunity To Rebuild The Agency — But Not The Way It Was

Rick Pazdur, formerly the FDA’s top oncology official, said the FDA is at a critical juncture that could determine the direction of the world’s top regulator of medicines.

CMS Finalizes Rule To Simplify Payer-Provider Disputes Under No Surprises Act 

Provider groups largely welcomed the reforms — though some industry leaders said additional changes are still needed to address alleged misuse and improve transparency.

Massachusetts Attorney General Sues UnitedHealthcare, Alleges $100M MassHealth Fraud

The Massachusetts attorney general sued UnitedHealthcare, alleging the insurer improperly inflated MassHealth members’ health risk scores to secure at least $100 million in excess payments.

Healthcare Moves: A Monthly Summary Of Hires, Exits, And Layoffs

Abridge, Highmark Health, and Merck named new executives. There were also layoffs at organizations including Innovaccer, Intermountain Health, and Novartis.

60 Cancer Patient And Provider Orgs Call On RFK Jr. To Protect USPSTF

Healthcare organizations urged HHS Secretary Robert F. Kennedy Jr. to protect the U.S. Preventive Services Task Force, warning that disruptions could threaten access to preventive care for millions of Americans.

Hospitals Take CVS To Court Over Alleged $250M 340B Scheme

Three health systems are suing CVS Health, alleging its pharmacy benefit manager diverted roughly $250 million in savings from the 340B program through 'spread pricing' between 2020 and 2025.

Takeda Vows Appeal Of $885M Jury Verdict In ‘Pay-For-Delay’ Antitrust Case

Pharmacies and wholesalers claimed Takeda Pharmaceutical delayed generic competition from entering the market, forcing them to overpay for a gastrointestinal drug.

Will Mark Cuban’s Cost Plus Wellness Appeal To Employers?

Employer advocates said Cost Plus Wellness could help spur more direct contracting and transparency in healthcare, though they questioned whether the model can scale and adequately measure provider quality and outcomes.